4.6 USD
+0.06 (+1.32%)
4.59 USD
-0.01 (-0.22%)
We assign a fundamental rating of 3 out of 10 to NEUP. NEUP was compared to 531 industry peers in the Biotechnology industry. NEUP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEUP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
NEUP had negative earnings in the past year.
In the past year NEUP had a positive cash flow from operations.
In the past 5 years NEUP always reported negative net income.
NEUP had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -1.29%, NEUP belongs to the best of the industry, outperforming 87.95% of the companies in the same industry.
With an excellent Return On Equity value of -1.95%, NEUP belongs to the best of the industry, outperforming 89.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.29% | ||
| ROE | -1.95% | ||
| ROIC | N/A |
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NEUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEUP has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, NEUP has less shares outstanding
NEUP has a better debt/assets ratio than last year.
2.2 Solvency
NEUP has an Altman-Z score of -6.33. This is a bad value and indicates that NEUP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NEUP (-6.33) is worse than 67.04% of its industry peers.
The Debt to FCF ratio of NEUP is 0.43, which is an excellent value as it means it would take NEUP, only 0.43 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.43, NEUP belongs to the top of the industry, outperforming 95.10% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that NEUP is not too dependend on debt financing.
NEUP's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. NEUP outperforms 48.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.43 | ||
| Altman-Z | -6.33 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
A Current Ratio of 3.56 indicates that NEUP has no problem at all paying its short term obligations.
NEUP has a Current ratio (3.56) which is in line with its industry peers.
NEUP has a Quick Ratio of 3.56. This indicates that NEUP is financially healthy and has no problem in meeting its short term obligations.
NEUP has a Quick ratio of 3.56. This is comparable to the rest of the industry: NEUP outperforms 43.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.56 |
3. Growth
3.1 Past
NEUP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -130.00%.
NEUP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.98% yearly.
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-33.45%
Revenue growth 5Y-59.98%
Sales Q2Q%N/A
3.2 Future
NEUP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -180.80% yearly.
The Revenue is expected to grow by 14.87% on average over the next years. This is quite good.
EPS Next Y-104017.17%
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
EPS Next 5Y-180.8%
Revenue Next Year686792%
Revenue Next 2Y4405.1%
Revenue Next 3Y2711.32%
Revenue Next 5Y14.87%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NEUP. In the last year negative earnings were reported.
Also next year NEUP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, NEUP is valued cheaply inside the industry as 90.02% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 320.57 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NEUP's earnings are expected to grow with 165.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
5. Dividend
5.1 Amount
NEUP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.6
+0.06 (+1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners25.15%
Inst Owner Change9.76%
Ins Owners3.42%
Ins Owner ChangeN/A
Market Cap24.75M
Revenue(TTM)191.00K
Net Income(TTM)-370.00K
Analysts80
Price Target14.72 (220%)
Short Float %3.36%
Short Ratio0.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.73%
PT rev (3m)-31.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-141.21%
EPS NY rev (1m)1.59%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.58 | ||
| P/FCF | 320.57 | ||
| P/OCF | 320.57 | ||
| P/B | 1.3 | ||
| P/tB | 4.45 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.02
EYN/A
EPS(NY)-25.46
Fwd EYN/A
FCF(TTM)0.01
FCFY0.31%
OCF(TTM)0.01
OCFY0.31%
SpS2.91
BVpS3.53
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.29% | ||
| ROE | -1.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 0.49% |
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.43 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.56 | ||
| Altman-Z | -6.33 |
F-Score7
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-104017.17%
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
EPS Next 5Y-180.8%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-33.45%
Revenue growth 5Y-59.98%
Sales Q2Q%N/A
Revenue Next Year686792%
Revenue Next 2Y4405.1%
Revenue Next 3Y2711.32%
Revenue Next 5Y14.87%
EBIT growth 1Y93.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-445.42%
EBIT Next 3Y-94.85%
EBIT Next 5YN/A
FCF growth 1Y100.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.53%
OCF growth 3YN/A
OCF growth 5YN/A
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What is the fundamental rating for NEUP stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEUP.
What is the valuation status for NEUP stock?
ChartMill assigns a valuation rating of 2 / 10 to NEUPHORIA THERAPEUTICS INC (NEUP). This can be considered as Overvalued.
Can you provide the profitability details for NEUPHORIA THERAPEUTICS INC?
NEUPHORIA THERAPEUTICS INC (NEUP) has a profitability rating of 2 / 10.
Can you provide the financial health for NEUP stock?
The financial health rating of NEUPHORIA THERAPEUTICS INC (NEUP) is 6 / 10.